These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17343426)

  • 21. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug Safety Evaluation in China.
    Li L; Yin J
    Curr Allergy Asthma Rep; 2019 Jul; 19(9):39. PubMed ID: 31321555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.
    Yang Y; Zhou X; Gao S; Lin H; Xie Y; Feng Y; Huang K; Zhan S
    Drug Saf; 2018 Jan; 41(1):125-137. PubMed ID: 28815480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilance.
    Layton D; Shakir SA
    Drug Saf; 2015 Feb; 38(2):153-63. PubMed ID: 25564333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A New Erice Report Considering the Safety of Medicines in the 21st Century.
    Edwards IR
    Drug Saf; 2017 Oct; 40(10):845-849. PubMed ID: 28815462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methodologic challenges to studying patient safety and comparative effectiveness.
    Strom BL
    Med Care; 2007 Oct; 45(10 Supl 2):S13-5. PubMed ID: 17909371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From pharmacovigilance to pharmacoperformance.
    Peachey J
    Drug Saf; 2002; 25(6):399-405. PubMed ID: 12071776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 32. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 33. Decision making in drug safety-a literature review of criteria used to prioritize newly detected safety issues.
    Pacurariu AC; Coloma PM; Gross-Martirosyan L; Sturkenboom MC; Straus SM
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):327-334. PubMed ID: 27878889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A call for international harmonization in therapeutic risk management.
    Hirst C; Cook S; Dai W; Perez-Gutthann S; Andrews E
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):839-49; discussion 850-1. PubMed ID: 16981215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health].
    Micallef J; Jouanjus É; Mallaret M; Lapeyre Mestre M
    Therapie; 2019 Dec; 74(6):579-590. PubMed ID: 31694770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug information by public health and regulatory institutions: Results of an 8-country survey in Europe.
    Formoso G; Font-Pous M; Ludwig WD; Phizackerley D; Bijl D; Erviti J; Pospíšilová B; Montastruc JL
    Health Policy; 2017 Mar; 121(3):257-264. PubMed ID: 28073580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The periodic safety update report as a pharmacovigilance tool.
    Klepper MJ
    Drug Saf; 2004; 27(8):569-78. PubMed ID: 15154828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signal detection methodologies to support effective safety management.
    van Manen RP; Fram D; DuMouchel W
    Expert Opin Drug Saf; 2007 Jul; 6(4):451-64. PubMed ID: 17688389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.